Everest Group to Hold Third Quarter 2026 Earnings Conference Call on Thursday, October 29, 2026 Business Wire Everest Group, Ltd. (“Everest”) (NYSE: EG) will hold its third quarter 2026 earnings conference call on Thursday, October 29, 2026, beginning at 8:00 am Eastern Time. Dial in details can be obtained by completing the registration form available at: https://dpregister.com/sreg/10211569/104bf682c06 The call can be accessed via a live, listen only webcast at www.investors.everestglobal.com where a [...]
IGI to Release Third Quarter and Nine Months 2026 Financial Results on November 3, 2026 Business Wire International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today announced that it expects to release financial results for the third quarter and first nine months of 2026, on Tuesday, November 3, 2026, after the close of the U.S. financial markets. The results, along with an accompanying slide presentation, will be posted in [...]
LivaNova to Announce Third-Quarter 2026 Results Business Wire LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. [...]
OCP Announces Date of Second Quarter and First Half 2026 Earnings September 22, 2026 OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. [...]
Argan, Inc. Reports Second Quarter Fiscal 2027 Results September 2, 2026 Record Revenue of $384 Million; Record Net Income of $53.3 Million
Argan, Inc. to Announce Second Quarter Fiscal 2027 Results and Host Conference Call on Wednesday, September 2, 2026 August 19, 2026 Argan, Inc. (NYSE: AGX) (“Argan” or the “Company”) today announced that the Company will release its second quarter fiscal 2027 financial results after the market closes on Wednesday, September 2, 2026. Management will host a webcast with an accompanying slide presentation and conference call on Wednesday, September 2, 2026 at 5:00 p.m. ET. Participants can [...]
ReNew Announces Results for the First Quarter for Fiscal Year 2027 (Q1 FY27), Ended June 30, 2026 August 18, 2026 ReNew Energy Global Plc (“ReNew”, “the Company”, “we” or “our”) (Nasdaq: RNW, RNWWW), a leading decarbonization solutions company, today announced its unaudited consolidated IFRS results for Q1 FY27. Operating Highlights: As of June 30, 2026, the Company’s portfolio consisted of ~20.5 GW (including 1.7 GW/6.2 GWh of BESS). Additionally, ReNew has 6.4 GW of solar [...]
Kolibri Global Energy Inc. Announces Another Record for Its Highest Quarterly Revenue of $22.5 Million With a 46% Production Increase and a 197% Net Income Increase for the Second Quarter of 2026 August 13, 2026 All amounts are in U.S. Dollars unless otherwise indicated: SECOND QUARTER HIGHLIGHTS Revenue, net of royalties was $22.5 million in the second quarter of 2026 compared to $10.8 million for the second quarter of 2025, an increase of 109% due to a 46% increase in production and a 41% increase in average prices Average production [...]
Organigram Reports Record Third Quarter Fiscal 2026 Results August 11, 2026 Record Quarterly Revenue and Adjusted EBITDA(1) Driven by Acquisition of Sanity Group
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile August 10, 2026 Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% Both divesiran dose groups showed substantial primary endpoint efficacy; 93.8% response rate at Q6W and 81.3% response rate at Q12W Divesiran was observed to be well tolerated with no new safety findings Phase 3 PV trial evaluating divesiran Q12W vs. placebo anticipated to initiate in 1H’27 Investor conference call and webcast to be held today, August 10, 2026 at 8:00 a.m. ET